CIAM
MNPR icon

Caitong International Asset Management’s Monopar Therapeutics MNPR Stock Holding History

Caitong International Asset Management’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.37K Sell
25
-2,854
-99% -$172K ﹤0.01% 1338
2025
Q4 		$188K Buy
+2,879
New +$235K 0.05% 222

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Caitong International Asset Management's MNPR Position: Q1 2026 in Review

Caitong International Asset Management reduced its Monopar Therapeutics (MNPR) stake by 99% in Q1 2026, selling an estimated $172K and leaving 25 shares worth $1.37K. The position accounts for ﹤0.01% of the portfolio, ranked #1338.

Caitong International Asset Management first reported a position in MNPR in Q4 2025 and has held it in 2 quarters since. The position peaked at $188K in Q4 2025. 82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.

  • Caitong International Asset Management held 25 shares of Monopar Therapeutics worth $1.37K as of Q1 2026.
  • Caitong International Asset Management sold 2,854 Monopar Therapeutics shares in Q1 2026, an estimated $172K.
  • Monopar Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #1338 holding.
  • Caitong International Asset Management first reported a position in Monopar Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Caitong International Asset Management's Monopar Therapeutics position peaked at $188K in Q4 2025.
  • 82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.